This phase I trial is testing a new drug (KB004) in patients with recurrent glioblastoma.
This trial is treating patients with glioblastoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I Safety and Bioimaging Trial of KB004 in Patients With Glioblastoma
Other Non-Commercial Sponsor
Olivia Newton-John Cancer Research Institute
Participants in this trial will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned: 3.5mg/kg, 5.25 mg/kg and 7.9 mg/kg
Recruiting Hospitals Read More